Share this article
Share this article
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, revealed key data related to its engineered iPSC-derived NK-cell platform at the American Society of Gene & Cell Therapy 24th Annual Meeting. These data include the successful generation of functional NK cells from iPSCs engineered to contain a biallelic knockout of a key MHC class I gene. Exacis cell engineering strategy is designed to allow its ExaNK™ cells to evade surveillance by the patient s immune system, thus rendering the cells rejection resistant, or stealth , to enable increased persistence in patients without genotoxic pre-conditioning.